key: cord-0742984-c74k3h7a
authors: Ye, Chengjin; Park, Jun-Gyu; Chiem, Kevin; Dravid, Piyush; Allué-Guardia, Anna; Garcia-Vilanova, Andreu; Kapoor, Amit; Walter, Mark R.; Kobie, James J.; Plemper, Richard K.; Torrelles, Jordi B.; Martinez-Sobrido, Luis
title: Immunization with recombinant accessory protein-deficient SARS-CoV-2 protects against lethal challenge and viral transmission
date: 2022-03-14
journal: bioRxiv
DOI: 10.1101/2022.03.13.484172
sha: d826d44a1d083897c6365bf3f3159d3c515abf55
doc_id: 742984
cord_uid: c74k3h7a

Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) has led to a worldwide Coronavirus Disease 2019 (COVID-19) pandemic. Despite high efficacy of the authorized vaccines, protection against the surging variants of concern (VoC) was less robust. Live-attenuated vaccines (LAV) have been shown to elicit robust and long-term protection by induction of host innate and adaptive immune responses. We sought to develop a COVID-19 LAV by generating 3 double open reading frame (ORF)-deficient recombinant (r)SARS-CoV-2 simultaneously lacking two accessory open reading frame (ORF) proteins (ORF3a/ORF6, ORF3a/ORF7a, and ORF3a/ORF7b). Here, we report that these double ORF-deficient rSARS-CoV-2 have slower replication kinetics and reduced fitness in cultured cells as compared to their parental wild-type (WT) counterpart. Importantly, these double ORF-deficient rSARS-CoV-2 showed attenuation in both K18 hACE2 transgenic mice and golden Syrian hamsters. A single intranasal dose vaccination induced high levels of neutralizing antibodies against different SARS-CoV-2 VoC, and also activated viral component-specific T-cell responses. Notably, the double ORF-deficient rSARS-CoV-2 were able to protect, as determined by inhibition of viral replication, shedding, and transmission, against challenge with SARS-CoV-2. Collectively, our results demonstrate the feasibility to implement these double ORF-deficient rSARS-CoV-2 as safe, stable, immunogenic and protective LAV for the prevention of SARS-CoV-2 infection and associated COVID-19 disease.

LAVs, which can induce broad host immune responses and activate both innate and 300 adaptive immunity, are attractive for prophylaxis against emerging and re-emerging 301 pathogens that undergoing rapid antigenic drift, such as SARS-CoV-2 25 . In this study, we 302 used our established BAC-based reverse genetic system 21 to generate 3 potential SARS-303 an MLD50 greater than 2x10 5 PFU, and rSARS-CoV-2 Δ3a/Δ6 showed a MLD50 of ~2x10 5 320 PFU, which is about 400-fold higher than its WT counterpart, suggesting adequate 321 15 attenuation of these two rSARS-CoV-2 Δ3a/Δ6 and rSARS-CoV-2 Δ3a/Δ7b LAV 322 candidates. Although all mice infected with rSARS-CoV-2 Δ3a/Δ7b (2x10 5 PFU) 323 succumbed to infection, they still showed an increased survival time than K18 hACE2 324 transgenic mice infected with rSARS-CoV-2 WT. In addition, we noticed that pathological 325 lesions were observed on the lungs of the 3 double ORF-deficient rSARS-CoV-2-infected 326 K18 hACE2 mice at both 2 and 4 dpi, although reduced as compared to the pathological 327 lesions observed in mice infected with rSARS-CoV-2 WT. However, viral replication of 328 any LAV candidate was significantly reduced compared to that of rSARS-CoV-2 WT-329 infected K28 hACE2 transgenic mice. 330 Priming the immune system with one immunogen and then boosting with a different 331 immunogen is known to enhance immunity of the host 29,30 . Typically, the booster LAV is 332 provided to a higher dose than the prime LAV so that the boost LAV is not neutralized by 333 the immune response elicited by the prime vaccination 29 . In this study, we have 334 generated 3 SARS-CoV-2 LAV candidates, which have shown different virulence in K18 335 hACE2 transgenic mice, providing flexibility for designing different immunization protocols. 336

Notably, in all cases, the 3 SARS-CoV-2 LAV candidates were more attenuated than a 337 natural SARS-CoV-2 isolate, with rSARS-CoV-2 Δ3a/Δ7b being the most attenuated virus 338 and rSARS-CoV-2 Δ3a/Δ7a the most virulent; and rSARS-CoV-2 Δ3a/Δ6 having an 339 intermediate phenotype. It is worth noting that the K18 hACE2 transgenic mouse model 340 is highly sensitive to SARS-CoV-2 infection and may not represent reflections observed 341 in other animal models, or humans 31-34 . 342

In the case of rSARS-CoV-2 Δ3a/Δ7b-infected K18 hACE2 transgenic mice, 2 of the 343 5-infected mice has some minimal body weight loss before 6 dpi. Of note, the fully 344 16 attenuated rSARS-CoV-2 Δ3a/Δ7b was able to provide, upon a single intranasal 345 administration, a protective effect in K18 hACE2 transgenic mice challenged with a lethal 346 dose of rSARS-CoV-2 mCherryNluc, and 100% of the rSARS-CoV-2 Δ3a/Δ7b-vaccinated 347 K18 hACE2 transgenic mice survived the challenge with SARS-CoV-2, suggesting that The natural isolate SARS-CoV-2 of USA-WA1/2020 (NR-52281), and α (NR-54000), 428 β (NR-54008), δ (NR-55611), and ο (NR-56461) VoC were obtained from BEI Resources. 429

The rSARS-CoV-2 WT was generated previously 21 , and the rSARS-CoV-2 expressing 430 mCherryNluc (rSARS-CoV-2 mCherryNluc) was generated using the previously describe 431 strategy 24 . 432

The BAC harboring the entire viral genome of SARS-CoV-2 USA-WA1/2020 strain 434 to visualize the plaques, as previously described 42 . Number of plaques were measured 530 by using an ELISPOT, and viral neutralization was quantified using a sigmoidal dose 531 response curve. Mock-infected cells and SARS-CoV-2-infected cells in the absence of 532 serum were included as internal controls. Neutralizing titer at 50% inhibition (NT50) was 533 calculated for each serum sample. 534

Macroscopic pathology scoring was evaluated using ImageJ software to determine 536 the percentage of the total surface area of the lung (dorsal and ventral view) affected by 537 consolidation, congestion, and atelectasis, as previously described 43 . 538 At 2 and 4 dpi, four mice per group were humanely sacrificed to collect lungs and nasal 560 turbinates, and gross images of lungs were taken using an iPhone 6s (Apple). Then, nasal 561 turbinates and lungs were homogenized and processed as previously described 22 . 562

Tissue homogenates were centrifuged at 12,000x g for 5 min at 4°C, and clarified 563 supernatant were collected for further measurement of viral titers and cytokine and 564 chemokine induction. Another set of five-week-old K18 hACE2 transgenic mice (n=5) 565

were mock infected or infected (IN, 2x10 5 PFU) with double ORF-deficient rSARS-CoV-2 566 or rSARS-CoV-2 WT to evaluate body weight changes and survival rate daily for 21 days. 567

The surviving mice were bled to collect serum to assess total IgG levels against viral full- Reporter mCherry expression in the lungs of hamsters were evaluated under an IVIS, as 611 previously described above. Thereafter, all lungs and nasal turbinates were collected and 612 homogenized in 2 ml of PBS, and viral titers and Nluc activity were determined in the 613 clarified supernatant of lung and nasal turbinate homogenate, as previously described 614

above. 615

Data representative of three independent experiments in triplicate have been used. 617

All data represent the mean ± standard deviation (SD) for each group and analyzed by 618 SPSS13.0 (IBM). A two-tailed Student's t-test was used to compare the mean between 619 two groups. P values less than 0.05 (P<0.05) were considered statistically significant. • rSARS-CoV-2 A3a/A7b 0 ........................................... .......i.....::>--il,.......,.......,.......,.......,.. ...i ......... 

Seasonality of Respiratory Viral 645

Origin and evolution of pathogenic coronaviruses

Molecular Architecture of the SARS-CoV-2 Virus

Characteristics of SARS-CoV-2 and COVID-652

The ORF3a protein of SARS-CoV-2 induces apoptosis in cells

SARS-CoV-2 Orf6 hijacks Nup98 to block STAT nuclear import and 656 antagonize interferon signaling

Structural insight reveals SARS-CoV-2 ORF7a as an 659 immunomodulating factor for human CD14(+) monocytes. Iscience 24

SARS-CoV-2 suppresses IFNbeta production mediated by 662

NSP1, 5, 6, 15, ORF6 and ORF7b but does not suppress the effects of added 663

Immune evasion via SARS-CoV-2 ORF8 protein?

SARS-CoV-2 mRNA vaccine design enabled by prototype 667 pathogen preparedness

Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine

Evidence for increased breakthrough rates of SARS-CoV-2 672 variants of concern in BNT162b2-mRNA-vaccinated individuals

Serum Neutralizing Activity of mRNA-1273 against SARS-CoV-2 675

Yellow fever live attenuated vaccine: A very successful live 677 attenuated vaccine but still we have problems controlling the disease

The transmission of 680 yellow fever to Macacus rhesus

Learning immunology from the yellow fever vaccine: innate immunity 683 to systems vaccinology

Loss of furin cleavage site attenuates SARS-CoV-2

Scalable live-attenuated SARS-CoV-2 vaccine candidate 687 demonstrates preclinical safety and efficacy

CoV-2 vaccine candidates by genome recoding

Contribution of SARS-CoV-2 Accessory Proteins to Viral 693

Pathogenicity in K18 Human ACE2 Transgenic Mice

Rescue of SARS-CoV-2 from a Single Bacterial Artificial 696

Lethality of SARS-CoV-2 infection in K18 human angiotensin-698 converting enzyme 2 transgenic mice

A SARS-CoV-2 Infection Model in Mice Demonstrates 701 Protection by Neutralizing Antibodies

Analysis of SARS-CoV-2 infection dynamic in vivo using reporter-704 expressing viruses

The Future of SARS-CoV-2 Vaccination -Lessons from Influenza